Global Monoclonal Antibody Therapeutics Market Report 2023: Sector is Expected to Reach $534.2 Billion by 2030 at a CAGR of 12.7%
08 juin 2023 06h18 HE
|
Research and Markets
Dublin, June 08, 2023 (GLOBE NEWSWIRE) -- The "Monoclonal Antibody Therapeutics Market, By Source, by Application, By Distribution Channel, and By Region - Size, Share, Outlook, and Opportunity...
Genmab and argenx Enter Partnership to Advance Antibody Therapies in Immunology and Oncology
17 avr. 2023 02h00 HE
|
Genmab A/S
Media ReleaseCOPENHAGEN, Denmark; April 17, 2023 Genmab and argenx have entered a multiyear collaboration bringing together capabilities to jointly discover, develop and commercialize antibody...
Antibody Drug Conjugates Contract Global Market Report 2022: Increase in Research on Antibody Therapeutics Fuels Sector
29 déc. 2022 07h13 HE
|
Research and Markets
Dublin, Dec. 29, 2022 (GLOBE NEWSWIRE) -- The "Antibody Drug Conjugates Contract Market by Condition, by Linker, and by Region - Global Forecast to 2023-2033" report has been added to ...
$264 Worldwide Monoclonal Antibody Therapeutics Industry to 2027 - Featuring AbbVie, Amgen, Bayer and Biogen Among Others
01 nov. 2022 05h28 HE
|
Research and Markets
Dublin, Nov. 01, 2022 (GLOBE NEWSWIRE) -- The "Global Monoclonal Antibody Therapeutics Market (2022-2027) by Source, End-Users, Applications, and Geography, Competitive Analysis and the Impact of...
Global Antibody Therapeutics Market Analysis Report 2022-2027 - Key Manufacturers are Striving to Reduce In-house Operations to Leverage the Capabilities of CDMOs
26 sept. 2022 04h38 HE
|
Research and Markets
Dublin, Sept. 26, 2022 (GLOBE NEWSWIRE) -- The "Global Antibody Therapeutics Growth Opportunities" report has been added to ResearchAndMarkets.com's offering. This research service offers an...
Emergent BioSolutions’ COVID-19 Human Immune Globulin Product Candidate to be Evaluated in NIH-Sponsored Phase 3 Clinical Trial (INSIGHT-012) of Hyperimmune Intravenous Immunoglobulin for Outpatient Treatment of COVID-19
25 août 2021 06h30 HE
|
Emergent BioSolutions
NIAID has initiated a Phase 3 clinical trial to evaluate the efficacy and safety of hyperimmune globulin products, including Emergent’s COVID-19 Human Immune Globulin (COVID-HIG), for potential...